Code intelligence

FDA-NDA021130 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA021130.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

no upcoming deadlines

FDA Approval: ZYVOX (LINEZOLID) — Type 1 - New Molecular Entity

Policy FDA-NDA021130 · Infectious Disease

High

ZYVOX (Linezolid) is an oral antibacterial drug that falls under Medicare Part D for billing. Since it is not an injectable, a J-code assignment is not applicable. No pass-through payment or ASP+6% wi